Revelation Biosciences, Inc. - REVB STOCK NEWS

Revelation Biosciences CEO to present at 2023 ROTH Healthcare Opportunities Conference on Oct 12. One-on-one investor meetings scheduled.

Revelation Biosciences appoints Dr. Lakhmir Chawla to its Board of Directors. Dr. Chawla brings expertise in nephrology, critical care medicine, and drug development. Positive impact on stock expected.

Revelation Biosciences Inc. (NASDAQ: REVB) reported its financial results for the three and six months ended June 30, 2023. The company had $15.7 million in cash and cash equivalents as of June 30, 2023, compared to $5.3 million as of December 31, 2022. Net cash used for operating activities for the six months ended June 30, 2023, was $3.6 million, a decrease from $8.5 million for the same period in 2022. The net loss for the three months ended June 30, 2023, was $1.4 million, compared to a net loss of $1.8 million for the same period in 2022. Net income for the six months ended June 30, 2023, was $4.7 million, primarily due to the change in fair value of the warrant liability creating an $8.2 million gain.

Revelation Biosciences Inc. (NASDAQ: REVB) reported its year-end 2022 financial results, showcasing a significant cash increase to $5.3 million, up from $1.3 million in 2021, primarily from a $15.6 million public offering. The company plans to initiate a combined Phase 1a clinical study for REVTx-100 and REVTx-300 in the latter half of 2023, supported by positive preclinical data. Revelation's net loss for 2022 was $10.8 million, or $20.09 per share, an improvement from $12.0 million in 2021, indicating reduced operational expenses. The firm anticipates sufficient funds to support operations through June 2024.

Revelation Biosciences Inc. (NASDAQ: REVB) has appointed Dr. Julia Bohannon and Dr. Antonio Hernandez to its Scientific Advisory Board. Dr. Bohannon, an Associate Professor at Vanderbilt University Medical Center, specializes in immunomodulatory treatments for burn injuries. Dr. Hernandez, also from Vanderbilt, focuses on enhancing innate immunity and developing therapies for critical care patients. Both bring significant expertise and will guide the company's PHAD-based technology for preventing and treating healthcare-associated infections. CEO James Rolke expressed excitement about their contributions to Revelation's ongoing efforts in immunologic therapies.

Revelation Biosciences Inc. (NASDAQ: REVB), focused on immunologic-based therapies, announced that CEO James Rolke will join a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, in Laguna Niguel, California. The chat is scheduled for March 14 at 12:30 p.m. PT in Healthcare - Salon 5. Attendees can access the live webcast via the Revelation website, with a replay available for 30 days. Mr. Rolke will also be available for one-on-one meetings.